menu
    • menu
    [{"orgOrder":0,"company":"Kane Biotech","sponsor":"University of Maryland School of Medicine\u2019s Institute of Human Virology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"DispersinB","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Biofilm","sponsorNew":"Kane Biotech \/ University of Maryland School of Medicine\u2019s Institute of Human Virology","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ University of Maryland School of Medicine\u2019s Institute of Human Virology"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DispersinB","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Marc Edwards","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Private Placement","leadProduct":"DispersinB","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Marc Edwards","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Marc Edwards"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"DispersinB","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Salud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Salud Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Salud Pharma"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"ProgenaCare Global","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Kane Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Kane Biotech"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Citric Acid","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"14","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"14","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"DispersinB","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"14","companyTruncated":"Kane Biotech \/ NRC IRAP"}]

    Find Clinical Drug Pipeline Developments & Deals by Kane Biotech

    Menu

    Kane Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : NRC IRAP

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kane Biotech to Participate in a Multinational Corporate Collaboration Project

                            Details : The funding will be used to develop a proof-of concept for its DispersinB Wound Gel, antibiofilm enzyme-based gel for treating chronic wounds.

                            Brand Name : DispersinB

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 03, 2024

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : NRC IRAP

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Biotech Signs Deal with Qatar Datamation For Wound Gel Distribution

                            Details : The agreement aims for the distribution of revyve antimicrobial wound gel indicated for diabetic foot ulcers, in the Qatar wound care market.

                            Brand Name : Revyve

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : NRC IRAP

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kane Biotech Receives Funding Support to Expand the Revyve Antimicrobial Wound Gel Family

                            Details : The funding will support the development of three additional products to build on Kane Biotech’s revyve Antimicrobial Wound Gel technology for management of ulcers.

                            Brand Name : Revye

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 13, 2024

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : NRC IRAP

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kane Biotech Receives FDA Approval to Increase Dosage of Revyve™ Wound Gel

                            Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.

                            Brand Name : Revye

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 23, 2024

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve™ Antimicrobial Wound Gel at Advanced Wound...

                            Details : revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult po...

                            Brand Name : Revye

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EDTA acid,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel

                            Details : coactiv+ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult pop...

                            Brand Name : coactiv+

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2023

                            Lead Product(s) : EDTA acid,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Sodium Citrate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Recipient : ProgenaCare Global

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+™ Antimicrobial Wound ...

                            Details : Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfa...

                            Brand Name : Coactiv+

                            Molecule Type : Small molecule

                            Upfront Cash : $0.5 million

                            April 20, 2023

                            Lead Product(s) : Edetate Calcium Disodium,Sodium Citrate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Recipient : ProgenaCare Global

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Sodium Citrate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Sponsor : Salud Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Biotech Announces First Distribution Agreement for its Coactiv+™ Antimicrobial Hydrogel

                            Details : The coactiv+™ (disodium EDTA) Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.

                            Brand Name : Coactiv+

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 04, 2023

                            Lead Product(s) : Edetate Calcium Disodium,Sodium Citrate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Sponsor : Salud Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : U.S. Department of Defense

                            Deal Size : $2.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States ...

                            Details : The funding supplements the clinical development of Kane’s DispersinB Hydrogel to treat biofilm-mediated antimicrobial resistance in non-healing chronic wounds. The DispersinB is a hydrogel wound dressing containing the enzyme DispersinB and the gellin...

                            Brand Name : DispersinB Hydrogel

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : U.S. Department of Defense

                            Deal Size : $2.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Marc Edwards

                            Deal Size : $1.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Kane Biotech Announces Update on Private Placement

                            Details : The funding will be used primarily for product development including DispersinB and general working capital. The Company has a portfolio of biotechnologies, intellectual property (81 patents) and products developed by the Company's own biofilm research e...

                            Brand Name : DispersinB

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 06, 2022

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Marc Edwards

                            Deal Size : $1.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth